Horizon Pharma traded at $80.84 this Friday July 1st, increasing $1.08 or 1.35 percent since the previous trading session. Looking back, over the last four weeks, Horizon Pharma gained 12.50 percent. Over the last 12 months, its price fell by 15.68 percent. Looking ahead, we forecast Horizon Pharma to be priced at 77.71 by the end of this quarter and at 69.03 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
80.84
Daily Change
1.35%
Yearly
-15.68%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,812.00 53.00 1.41% 2.69%
AbbVie 153.80 0.64 0.42% 33.54%
Aerie Pharmaceuticals 8.36 0.86 11.47% -47.78%
ALKERMES 30.53 0.74 2.48% 20.67%
Amgen 245.55 2.25 0.92% -1.27%
AstraZeneca 10,808.00 54.00 0.50% 24.54%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Cara Therapeutics 8.62 -0.51 -5.59% -40.06%
Coherus Biosciences 7.83 0.59 8.15% -42.97%
Endo International 0.57 0.10 22.42% -86.74%
Horizon Pharma 80.84 1.08 1.35% -15.68%
Jazz Pharmaceuticals 158.58 2.57 1.65% -12.63%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Novartis 81.65 1.32 1.64% -3.02%
Prestige Brands 59.58 0.78 1.33% 14.14%
Pacira 57.85 -0.45 -0.77% -2.41%
Pfizer 52.31 -0.12 -0.23% 31.66%
Perrigo 41.02 0.45 1.11% -12.56%
Revance Therapeutics 14.33 0.51 3.69% -52.85%
Supernus Pharmaceuticals 29.35 0.43 1.49% -3.36%
Teva Pharmaceutical Industries 7.89 0.37 4.92% -19.74%
Bausch Health Companies Inc 10.91 0.15 1.39% -70.44%
Xeris Pharmaceuticals Inc 1.50 -0.04 -2.60% -64.71%
Zoetis 174.21 2.32 1.35% -9.60%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Horizon Pharma
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.